Foghorn Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Foghorn Therapeutics Inc. (FHTX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-86.62-98.43-108.88-101.32-68.80
Depreciation & Amortization3.123.453.323.381.33
Stock Based Compensation11.8916.1914.348.382.96
Change in Working Capital-32.27-41.88281.5537.4528.70
Change in Accounts Receivable0.000.00300.00-300.000.00
Change in Accounts Payable-2.480.851.610.140.47
Change in Other Working Capital5.685.21-5.844.6113.66
Other Operating Activities5.685.214.588.984.73
Net Cash from Operating Activities-100.41-118.11193.61-50.25-31.29
Investing Activities
Capital Expenditures-0.91-1.22-1.213.31-16.18
Purchases of Investments-261.47-73.90-243.11-99.98-92.98
Sales/Maturities of Investments232.47219.58-243.1139.490.00
Net Cash from Investing Activities-29.90144.45-244.3236.17-108.91
Financing Activities
Debt Repayment0.000.000.00-21.210.00
Common Stock Issued103.401.781.7642.21123.34
Other Financing Activities-0.590.000.000.000.00
Net Cash from Financing Activities105.431.781.7622.42217.47
Summary
Net Change in Cash-24.8828.12-48.958.3477.27
Cash at Beginning of Period82.0453.92102.8794.530.00
Cash at End of Period57.1682.0453.92102.870.00
Free Cash Flow-101.31-119.33192.40-53.56-47.47
Supplemental Disclosures
Interest Paid0.000.000.001.720.66
Income Taxes Paid0.863.550.000.000.00